Spyre Therapeutics, Inc. · NASDAQ:SYRE
Sloan Sheldon sold 78,333 Spyre Therapeutics, Inc. shares (Form 4)
Traded May 1, 2026 · Filed May 1, 2026
On May 1, 2026, Sloan Sheldon (Chief Medical Officer) sold 78,333 Spyre Therapeutics, Inc. shares at an average US$71.50 for US$5.6M under a trading plan, leaving 0 shares. Filed May 1, 2026 (Form 4).
- Sold
- 78,333 shares
- Price
- US$71.50 average (US$69.53 to US$75.37)
- Value
- US$5.6M
- Holding after
- 0 shares
- Trading plan
- Yes (Made under a plan set in advance)
- Role
- Chief Medical Officer
The filing in full
| Date | Security | Transaction | Shares | Price | Holding after | Ownership |
|---|---|---|---|---|---|---|
| May 1, 2026 | Common Stock | Option exercise | 78,333 | US$27.46 | 78,333 | Direct |
| May 1, 2026 | Common Stock | Sale | 21,306 | US$69.53 | 57,027 | Direct |
| May 1, 2026 | Common Stock | Sale | 19,656 | US$70.61 | 37,371 | Direct |
| May 1, 2026 | Common Stock | Sale | 8,777 | US$71.56 | 28,594 | Direct |
| May 1, 2026 | Common Stock | Sale | 12,777 | US$72.94 | 15,817 | Direct |
| May 1, 2026 | Common Stock | Sale | 10,358 | US$73.74 | 5,459 | Direct |
| May 1, 2026 | Common Stock | Sale | 5,059 | US$74.60 | 400 | Direct |
| May 1, 2026 | Common Stock | Sale | 400 | US$75.37 | 0 | Direct |
Source
Related
- Spyre Therapeutics, Inc.
- Sloan Sheldon
- Spyre Therapeutics, Inc. shareholders
- Form 4 · Sloan Sheldon · Jul 2, 2026
- Form 4 · Sloan Sheldon · Jun 3, 2026
- Form 4 · Sloan Sheldon · Apr 3, 2026
- Schedule 13D/A · Harwin Peter Evan · Oct 9, 2026
- Form 4 · Burrows Scott L · Oct 2, 2026
- Form 4 · King-Jones Heidy · Oct 2, 2026
- Form 4 · Turtle Cameron · Oct 2, 2026
- Schedule 13G · Paradigm Biocapital Advisors LP · Oct 1, 2026